Effects of positive airway pressure therapy on cardiovascular and metabolic markers in males with obstructive sleep apnea

• Autor(a) principal: Feliciano, A.
• Data de Publicação: 2017
• Outros Autores: Oliveira, M.J., Cysneiros, A., Martinho, C., Reis, R.P., Penque, D., Pinto, P., Bárbara, C.
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
• Texto Completo: http://hdl.handle.net/10400.18/5472
• topic: Glucose Metabolism; HOMA-IR; Homocysteine; Lipid Metabolism; Obstructive Sleep Apnea; PAP; Genómica Funcional e Estrutural

Introduction: Obstructive sleep apnea syndrome (OSAS) is associated with cardiovascular/ metabolic complications. Some analytical parameters (homocysteine, glycemic and lipidic profiles) are recognized markers of these consequences. Limited data is available on the association of these markers and OSAS’s severity/response to positive airway pressure therapy (PAP). Material and methods: In this prospective study we analyzed polysomnographic and analytical data of male patients admitted to sleep laboratory. The aim was to evaluate metabolic/cardiovascular markers in snorers and OSAS patients, to relate with sleep parameters and PAP response. One-hundred and three patients were included, and 73 (71%) were OSAS patients. OSAS patients were similar to snorers except for higher body mass index (BMI) and dyslipidemia. Severe OSAS patients showed higher glycemia, HbA1c, insulin, and insulin resistance, and lower HDL cholesterol in comparison to mild---moderate (p < 0.05, p < 0.05, p < 0.001, p < 0.001, p < 0.05, respectively). Glycemic profile and triglycerides were slightly correlated with OSAS severity. 46 OSAS patients were submitted to 6 months of PAP, with a statistical decrease in mean values of homocysteine, glycemia, total and LDL cholesterol(p < 0.05, p < 0.05, p < 0.05, respectively), and in glycemia and LDL cholesterol in severe grouponly (p < 0.05, p < 0.05, respectively).Results: This study demonstrated an association between glucose metabolism parameters andtriglycerides with OSAS severity underlying the complexity of the process leading to cardiovas-cular/metabolic complications in this disorder. Moreover, homocysteine, glycemic and lipidicprofiles changed significantly after 6 months of PAP therapy in OSAS, supporting its cardiovas-cular and metabolic protective effect.Conclusion: Our study has reinforced the importance of analytical cardiovascular/metabolicevaluation as complementary tool of diagnosis/treatment response in OSAS.